Multi-centre, open-label extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD 1839.

Trial Profile

Multi-centre, open-label extension trial of treatment with ZD1839 (Iressa) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD 1839.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 May 2009

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Registrational
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2009 Actual end date changed from 1 Mar 2003 to 1 Oct 2003.
    • 04 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top